Novo Nordisk shares surged 9.9% Monday after telehealth firm Hims & Hers Health discontinued its $49 compounded weight-loss pill containing semaglutide, the key ingredient in Novo's Wegovy and Ozempic. The Danish pharma giant and the FDA had pressured Hims to halt sales of the unauthorized product over the weekend.

Regulators aim to tighten oversight of GLP-1 copycats after Novo warned compounded versions threaten pricing power in the $100 billion obesity drug market. The FDA cited safety risks and potential federal law violations, while Novo plans legal action against Hims. Rival Eli Lilly endorsed the crackdown as competition intensifies.

The rebound follows a brutal week where Novo lost $50 billion in market value after forecasting 2026 revenue could drop 13% amid price pressures. President Trump's push for lower drug costs and Lilly's stronger U.S. prescription trends have squeezed Novo's dominance in high-margin weight-loss therapies.

Quick Fact: Novo Nordisk lost $50 billion in market value last week.